Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with Anti-PD-1 and Chemotherapy in Locally Advanced TNBC
NCT06955156Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in triple-negative breast cancer (TNBC). Primary endpoint: Incidence of >= grade 3 neutropenia during chemotherapy. Started Jul 2023; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06955156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955156.